Document is current
Any future updates will be listed below
-
Authors
Haaksma, Lukas H. https://orcid.org/0009-0008-2179-4870
Palmieri, Raffaele
Reuvekamp, Tom https://orcid.org/0009-0001-1346-6606
Tettero, Jesse M. https://orcid.org/0000-0002-0811-0824
Ngai, Lok Lam https://orcid.org/0000-0003-0969-3766
Bachas, Costa https://orcid.org/0000-0001-5983-6193
Kelder, Angèle
Scholten, Willemijn J.
Gradowska, Patrycja
Arena, Valentina
João Simione, Anderson
Maurillo, Luca
Venditti, Adriano https://orcid.org/0000-0002-0245-0553
Löwenberg, Bob https://orcid.org/0000-0001-8982-5217
Ossenkoppele, Gert J.
de Leeuw, David C. https://orcid.org/0000-0003-4591-8467
Ikoma-Colturato, Maura R. V. https://orcid.org/0000-0002-1473-9696
Buccisano, Francesco
Cloos, Jacqueline https://orcid.org/0000-0001-9150-8026
- License Information
-
More Information
Article History
Received: 5 August 2025
Revised: 14 October 2025
Accepted: 21 November 2025
First Online: 10 December 2025
Competing interests
: AV: BMs celgene: Consultancy, Other: invited speaker; Servier: Consultancy, Other: invited speaker; astellas: Consultancy, Other: invited speaker; Jazz: Consultancy, Other: invited speaker, Research Funding; Pfizer: Consultancy, Other: invited speaker; AstraZeneca: Consultancy; Janssen: Consultancy, Other: invited speaker; Glycostem: Consultancy; laboratories Delbert: Consultancy; Beigene: Consultancy; Abbvie: Consultancy, Other: invited speaker; Gilead: Consultancy, Other: invited speaker; Menarini: Consultancy, Other: invited speaker; Istituto Gentili: Consultancy. DCeL: AbbVie: Consultancy; Servier: Consultancy; Immedica: Consultancy Takeda: Membership on an entity’s Board of Directors or advisory committees; Daiichi Sankyo: Consultancy; Immedica Pharma: Scientific advisory board. FB: Jazz Pharmaceuticals: Honoraria; Delbert: Honoraria; Servier: Honoraria. JC: Novartis, Genentech: Research Funding; Navigate, BD biosciences: Patents & Royalties: MRD measurement; Astellas: Speakers Bureau; Merus: Research Funding; Genentech: Research Funding.
: The study was approved by the institutional review boards of all included trials (EudraCT numbers for HOVON 42A, HOVON 81, HOVON 92, HOVON 102, HOVON 103, HOVON 132, and GIMEMA AML-1310 are shown in Supplementary Table ), and by the institutional ethics committee of Hospital Amaral Carvalho for patients included from the AMLSG Brazil (CAAE: 69725623.0.0000.5434). All patients provided written informed consent and the study was conducted according to the Declaration of Helsinki.
